Latest Safety News

Aurelia Metals has successfully met its FY25 production and cost guidance, while advancing key mining projects and maintaining a robust cash position of $110 million.

Aurelia Metals has successfully met its FY25 production and cost guidance, driven by a strong ramp-up at Federation Mine and the start of development at Great Cobar. The company’s solid quarterly performance underpins its growth ambitions for FY26.

Tryptamine Therapeutics has begun recruiting patients for a pioneering clinical trial testing IV-infused psilocin combined with psychotherapy to treat Binge Eating Disorder, aiming to deliver faster and more controlled treatment outcomes.

Nyrada has successfully dosed and discharged the final participants in its Phase I trial of Xolatryp, reporting no adverse safety signals and setting the stage for Phase II development.

Regis Resources closed FY25 with gold production near the top of guidance and a robust cash and bullion position of $517 million. The company’s FY26 outlook maintains steady production while ramping up growth investments amid ongoing legal and exploration developments.

Rincon Resources launches a fully underwritten Loyalty Option Entitlement Offer to raise nearly $100,000, aiming to support upcoming exploration at its Western Australian gold and critical metals projects.

Hillgrove Resources reported operational gains and exploration success in Q2 2025, despite lower copper output due to grade variability. The Nugent acceleration project is progressing ahead of schedule, setting the stage for increased throughput and cost efficiencies in 2026.

Robex Resources reports steady progress on its Kiniero Gold Project in Guinea, maintaining schedule and budget for first gold production in late 2025. Key construction milestones and drilling results underpin confidence in the project’s near-term potential.

Yancoal’s June quarter report reveals steady coal production despite weather disruptions and a dip in realised prices, supported by a robust $1.8 billion cash reserve. The company remains confident in hitting upper-end production guidance amid ongoing market volatility.

CuFe Ltd has enhanced the confidence level of its Orlando deposit resource at Tennant Creek, increasing the Indicated classification from 42% to 56% following a rigorous QAQC review. This upgrade supports the imminent release of the Orlando Scoping Study.

Clarity Pharmaceuticals has successfully completed recruitment for its pivotal Co-PSMA Phase II trial, testing its novel Cu-SAR-bisPSMA diagnostic against the current standard in detecting prostate cancer recurrence. This milestone advances their mission to improve early detection and treatment outcomes for men with low PSA levels.

Visionflex Group delivered a standout Q4 FY25, posting $2.1 million in cash receipts and securing transformative contracts that underpin its expanding virtual healthcare footprint.